Atlas Trials

A Study of Pyrotinib Plus Capecitabine Combined With SRT in HER2+ MBC With Brain Metastases

Clinical trial NCT05042791 · UNKNOWN

Trial details

NCT number
NCT05042791
Sponsor
Jiangxi Provincial Cancer Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
HER2-positive Metastatic Breast Cancer
Start date
2022-03-01
Primary completion
2025-09-30
Enrollment
362

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.